{"prompt": "['Non-Interventional Study Protocol', 'Study Short Title', 'Evaluation of the sensitivity and specificity of a novel quality of life (QoL)', 'tool to assess the treatment satisfaction in psoriasis patients', 'STUDY IDENTIFICATION No. 2020-A00652-37', 'Full Study Title', 'Evaluation of the sensitivity and specificity, compared to DLQI as a standard tool, of a novel', 'QoL questionnaire (treat to the PSOriasis patient satiSfactiOn TARGET) among moderate to', 'severe psoriasis patients treated with brodalumab (Kyntheum)', 'GPP statement:', 'This Non-Interventional Study will be conducted in compliance with the', 'Clinical Study Protocol, Good Pharmacoepidemiology Practices and', 'applicable regulatory requirement(s)', 'Sponsoring entity:', 'LEO Study ID: PSO-TARGET', 'LEO Pharma France', '2 rue Ren\u00e9 Caudron', 'Date: 25-05-2020', '215 avenue Georges Clemenceau', '78960 Voisins-Le-Bretonneux', 'Version: 2.0']['NIS-PSO-TARGET', 'Non-Interventional Study Protocol', 'Page 2 of 51', 'Study ID RCB: 2020-A00652-37', 'KEY STUDY PERSONNEL', 'STUDY MANAGER', 'MAIN PROTOCOL AUTHOR', 'BERTRAND B\u00e9n\u00e9dicte, Clinical Manager', 'SALTET DE SABLET Thibaut, Medical Writer', 'CLINACT', 'CLINACT', 'V\u00e9lizy Espace - Immeuble Santos Dumont', 'V\u00e9lizy Espace - Immeuble Santos Dumont', '13 avenue Morane Saulnier - CS 50730', '13 avenue Morane Saulnier - CS 50730', '78457 V\u00e9lizy-Villacoublay Cedex, France', '78457 V\u00e9lizy-Villacoublay Cedex, France', 'STATISTICIAN', 'CARRERE Florence, Head of Biometry /', 'Senior Biostatistician', 'STATITEC', 'V\u00e9lizy Espace - Immeuble Santos Dumont', '13 avenue Morane Saulnier - CS 50730', '78457 V\u00e9lizy-Villacoublay Cedex, France', 'THIS DOCUMENT CONTAINS TRADE SECRETS, AND/OR COMMERCIAL OR FINANCIAL INFORMATION, PRIVILEGED OR CONFIDENTIAL. DELI-', 'VERED IN CONFIDENCE AND RELIANCE THAT SUCH INFORMATION WILL NOT BE COPIED OR MADE AVAILABLE TO ANY THIRD PARTY', 'WITHOUT THE WRITTEN CONSENT OF LEO PHARMA A/S']['NIS-PSO-TARGET', 'Non-Interventional Study Protocol', 'Page 3 of 51', 'Study ID RCB: 2020-A00652-37', 'APPROVERS', 'The following person(s) within LEO Pharma (LEO) has/have approved this Study Protocol by', 'signing the Non-Interventional Study Protocol Approval Form adjoined as a separate page to', 'this document:', 'Nadine MacKenzie', 'Medical director, France and Benelux', 'NV', 'Sarah Moumane', 'Dermatology MSL manager, France', 'LIMAY', 'Ang\u00e8le GUILBOT', 'Scientific and Regulatory Director', 'CLINACT', 'V\u00e9lizy Espace - Immeuble Santos Dumont', 'Apple', '13 avenue Morane Saulnier - CS 50730', '78457 V\u00e9lizy-Villacoublay Cedex, France', 'Dr Ziad REGUIAI', 'International Co-ordinating Investigator', 'Polyclinique Reims-Bezannes', 'A', '89 Rue Victor De Broglie', '51430 Bezannes, FRANCE', 'THIS DOCUMENT CONTAINS TRADE SECRETS, AND/OR COMMERCIAL OR FINANCIAL INFORMATION, PRIVILEGED OR CONFIDENTIAL. DELI-', 'VERED IN CONFIDENCE AND RELIANCE THAT SUCH INFORMATION WILL NOT BE COPIED OR MADE AVAILABLE TO ANY THIRD PARTY', 'WITHOUT THE WRITTEN CONSENT OF LEO PHARMA A/S']\n\n###\n\n", "completion": "END"}